Molecular Targeted Agents and Biologic Therapies for Lung Cancer

Abstract

Tabulated below are “targeted” or novel agents that are being or have been evaluated in non-small cell lung cancer and small cell lung cancer. Only compounds that have entered clinical trials have been listed. The compounds are listed by class, and within each class, they are listed in the order of their phase of clinical development, with those in the latest phase being listed first. The classes are listed alphabetically, except for the first two categories (endothelial growth factor receptor and vascular endothelial growth factor receptor [VEGFR] inhibitors), because drugs from this category are approved for non-small cell lung cancer and are in clinical practice. Drugs that do not fall into specific broad categories are clumped under “others” at the end of the Table 1. Compounds that have multikinase activity, for instance, those that are both VEGFR and fibroblast growth factor receptor (FGFR) inhibitors are listed in the VEGFR inhibitor category if the compound is believed to be a predominant VEGFR inhibitor (e.g., BIBF 1120) and in the FGFR category if it is predominantly a FGFR inhibitor (e.g., brivanib or dovitinib). We have made every attempt to be current and comprehensive, and this table is essentially designed to be a quick reference tool; however, the information listed is dynamic and constantly evolving and therefore the reader is encouraged to look for further updates that may have been reported after the publication of this table. This is especially pertinent for compounds in later phases of testing. In the last column, the commonly reported toxicities are listed. This list is not intended to be comprehensive, but only the prototypic or most commonly seen “class effect” toxicities are noted. The toxicity column has been left blank for compounds very early in development for which toxicity data are not yet available. The phase of the trial is also listed. If the phase of development in lung cancer differs from the overall development of the agent, then this has been explicitly stated. Compounds still in phase I development with potential utility for lung cancer and/or are enrolling lung cancer patients are also included. When available, the generic name, trade names, and other accepted names or phrases used to refer to an agent have also been listed.